THYSSENKRUPP AG/S (OTCMKTS:TKAMY) and Eisai (OTCMKTS:ESALY) are both large-cap basic materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Insider & Institutional Ownership
0.1% of Eisai shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares THYSSENKRUPP AG/S and Eisai’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
THYSSENKRUPP AG/S has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Eisai has a beta of -0.21, meaning that its stock price is 121% less volatile than the S&P 500.
THYSSENKRUPP AG/S pays an annual dividend of $0.12 per share and has a dividend yield of 0.5%. Eisai pays an annual dividend of $0.62 per share and has a dividend yield of 0.7%. THYSSENKRUPP AG/S pays out 29.3% of its earnings in the form of a dividend. Eisai pays out 38.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
This is a breakdown of current ratings and price targets for THYSSENKRUPP AG/S and Eisai, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Earnings & Valuation
This table compares THYSSENKRUPP AG/S and Eisai’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|THYSSENKRUPP AG/S||$45.79 billion||0.32||-$718.18 million||$0.41||57.11|
|Eisai||$5.42 billion||5.00||$466.60 million||$1.63||56.03|
Eisai has lower revenue, but higher earnings than THYSSENKRUPP AG/S. Eisai is trading at a lower price-to-earnings ratio than THYSSENKRUPP AG/S, indicating that it is currently the more affordable of the two stocks.
Eisai beats THYSSENKRUPP AG/S on 8 of the 12 factors compared between the two stocks.
About THYSSENKRUPP AG/S
thyssenkrupp AG operates in the areas of mechanical, plant, and materials technologies in Germany and internationally. The company's Components Technology segment provides various components for automotive, construction, and engineering sectors, as well as for wind turbines. Its Elevator Technology segment is involved in the construction, modernization, and servicing of elevators, escalators, moving walks, and stairs and platform lifts, as well as passenger boarding bridges. The company's Industrial Solutions segment offers construction services, as well as naval shipbuilding services. Its Materials Services segment distributes materials, and provides technical services for the production and manufacturing sectors. The company's Steel Europe segment offers flat carbon steel products. thyssenkrupp AG was founded in 1811 and is headquartered in Essen, Germany.
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals worldwide. It offers Halaven and Lenvima, an anticancer agent; Aloxi, an antiemetic agent; Aricept, a treatment for Alzheimer's disease; Fycompa, an antiepileptic agent; Methycobal for peripheral neuropathy treatment; BELVIQ for anti-obesity treatment; and LYRICA for neuropathic pain treatment. The company also provides Lunesta, a non-benzodiazepine hypnotic agent for insomnia treatment; Pariet, a proton pump inhibitor; HUMIRA, a human anti-TNF-a monoclonal antibody; and epilepsy franchise products, including Zonegran, Zebinix, Fycompa, and Inovelo, which are antiepileptic agents. In addition, it offers Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome; Actonel, an osteoporosis treatment; and Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment. The company has strategic partnerships with Quintiles Inc. for developing six types of anticancer compound candidates; and Epizyme, Inc. to discover, develop, and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically defined patients. It also has collaboration agreement with Ono Pharmaceutical Co., Ltd. to develop Lenvima (lenvatinib mesylate), a multi-kinase inhibitor, as well as Opdivo, a human anti-human programmed cell death-1 monoclonal antibody, for the treatment of hepatocellular carcinoma; and Merck & Co., Inc. to develop and commercialize Lenvima. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.
Receive News & Ratings for THYSSENKRUPP AG/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for THYSSENKRUPP AG/S and related companies with MarketBeat.com's FREE daily email newsletter.